Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
AUSTIN, Texas, Sept. 06, 2017 -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, today announced that Eric E. Poma, Ph.D., Chief Executive and Chief Scientific Officer, will provide a corporate overview at the BioCentury 24th Annual Newsmakers in the Biotech Industry conference, being held September 8th at the Millennium Broadway Hotel in New York City.
Presentation Details:
Date: Friday, September 8
Time: 2:00pm Eastern Time
Location: The Millennium Broadway Hotel, Presentation Room 311
Webcast: http://www.wsw.com/webcast/biocentury4/mtem/index.aspx
About Molecular Templates
Molecular Templates is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases. For additional information, please visit Molecular Templates’ website at www.mtem.com.
Investor Contact: Andrew McDonald, Ph.D. [email protected] 646-597-6987
